Navigation Links
Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
Date:11/16/2009

therapy where cancer drugs are actively pumped out of cancer cells," said David Sherris, Ph.D., President and CEO of Paloma Pharmaceuticals. "This work adds to our mounting compendium of data showing P529 as a potent oral anti-tumor agent in variety of tumor animal models including breast, prostate and glioblastoma," said Dr. Sherris.

About the PI3K/Akt/mTOR Pathway

The PI3K/Akt/mTOR pathway has been implicated in a wide variety of biological responses and is considered a major therapeutic target in cancer. Activation of this signaling pathway, via direct or indirect mutagenic events, is common in many types of human cancer resulting in deregulation of PI3K/Akt/mTOR pathway in cancer. Thus, agents capable of inhibiting the PI3K/Akt/mTOR pathway are attractive targets for therapeutic intervention in cancer. Central within the signalling pathway are two distinct protein complexes, one of which regulates growth through the signal transduction protein S6K, TORC1, and the other that regulates cell survival through Akt, TORC2. These complexes define both rapamycin-sensitive and insensitive branches of the PI3K/Akt/mTOR pathway. Inhibition of the TORC2 pathway suppresses the formation of tumors driven by the loss of the PTEN tumor suppressor, a gene which when lost contributes to carcinogenicity. Inhibitors of TORC2 may then have beneficial effects as anti-cancer agents without toxicity to normal tissues since loss of TORC2 through genetic alteration does not appear to affect normal tissue. TORC1 antagonists as rapamycin and other such rapalogs have shown activity in both animal models of cancer and in human clinical trials. As inhibition of both TORC1 and TORC2 should result in more complete inhibition of PI3K/Akt/mTOR signaling up-regulated in cancer, dual inhibitors are of active interest for pharmaceutical development.

About Paloma Pharmaceuticals

Paloma Pharmaceuticals, Inc. is an early stage drug development company
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
2. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014  The management team at ... will hold a conference call on July 31, ... quarter ended June 30, 2014.  The call details ... , 8:30 am EDTDial-in numbers: , Toll free: ... 317-0790Webcast (live & archive): , www.columbialabs.com , ...
(Date:7/23/2014)... , July 23, 2014 ... business that is facing currency headwinds, increased price competition ... CEO Sir Andrew Witty points out that ... the development pipeline as reason to be confident about long-term ... drive long-term growth. CFO Simon Dingemans ...
(Date:7/23/2014)... DUBLIN , July 23, 2014 ... addition of the "Prepackaged Medical Kits and ... to their offering. ... worldwide markets for Prepackaged Medical Kits and Trays ... ENT Custom Trays, Ophthalmic Custom Trays, Custom Basin ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report 2
... April 21 BioMarin Pharmaceutical Inc. (Nasdaq: ... 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), ... Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. ... the first half of 2010. "We plan to ...
... studies; Data to be presented at AACR - ... and development company Esperance Pharmaceuticals today presented positive ... support the initiation of clinical trials in cancer. ... Cationic Lytic Peptide (CLYP(TM)) platform technology. EP-100 is ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 2BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 3BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 4First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 2First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 3
(Date:7/23/2014)... 2014 Inventor and entrepreneur Delegate Joe ... to the gas pump – sharing his passion for ... 30 at Noon. , With 24 patents granted and ... than anyone in the General Assembly since Thomas Jefferson. ... yard marker as seen on television, an instrument for ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Regularly checking the pulse ... researchers report. "Screening pulse is the method of ... age 65 who have never had a stroke. Our ... and easy way to identify people who might need ... study author Dr. Bernd Kallmunzer, of Erlangen University in ...
(Date:7/23/2014)... Northwest Agricultural and Forestry University in Shaanxi province, and ... of agreement that lays the groundwork for establishing the ... , The signing ceremony was held in the city ... of the U.S. Department of Agriculture and China,s Ministry ... landmark event for UC Davis and for our World ...
(Date:7/23/2014)... Rich Dad® Education, a leader in financial education, is ... to support Habit for Humanity of Lee and Hendry Counties. ... be donated to Habitat for Humanity. Additionally, all the items ... Habitat for Humanity ReStore thrift store located at 31 Willis ... the highlights of the yard sale was a visit from ...
(Date:7/23/2014)... July 23, 2014 Global Cardio Care, ... Enhanced External Counterpulsation (EECP), is celebrating the 100th ... therapy at the health center. , Weber has ... Since receiving ongoing EECP therapy since 1999, he no ... Soulati, CEO of Global Cardio Care, introduced the ...
Breaking Medicine News(10 mins):Health News:Celebrating Innovation and Invention 2Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2
... study researchers say Cocoa flavonols, shown// to benefit heart health, ... were found to increase blood flow to key areas of ... young women, researcher tested the brain’s activation during cognitive tasks ... flavonol-rich CocoaVia drink made by Mars once a day for ...
... tobacco smoke causes genetic damage// in the developing fetus, ... that smoking during pregnancy causes genetic damage in the ... ,Stephen G. Grant, Ph.D., associate professor of environmental and ... of Public Health re-examined data from the earlier study ...
... Elderly women, especially those above the age of 80yrs, ... their condition may remain undetected for long as well. ... of JAMA, said that about 75% of the participants ... have hypertension. ,The research, which was based on ...
... patients who don't respond well to conventional// therapy may ... portal www.eurekalert.org. ,Richard Fedorak, a professor of gastroenterology ... University of Bologna in Italy and the University of ... six-week period to 30 patients aged 18-65. ...
... Researchers have found that Leishmania parasite utilizes mannose for ... requires glucose. ,Associate Professor Malcolm McConville and ... of Melbourne have found a break thorough to control ... Leishmania is found to utilize sugar mannose in the ...
... The tempting red color of strawberries may be the culprit ... popular summer fruit, Swedish researchers say., ,"The allergen is ... but it is not clear exactly how. We need to ... ,Alm was quoted in the magazine Chemistry World, the publication ...
Cached Medicine News:Health News:Elderly Women Remain At Risk From Hypertension 2Health News:Metabolism cycle of Kala-Azar parasite revealed 2
Thermal Cautery, Reusable Base Unit. Burns at approximately 1200C (2200 F), non-sterile base unit with 1 non-sterile tip, 1 set single-use batteries. The two (2) AA batteries are replaceable (alkalin...
... The 2200 is ideal for applications ... of heat. , ,The autoclavable handpiece with ... thermal cautery electrodes, allowing the physician to ... variety of procedures., ,The 2200 includes the ...
... The 2201 is ideal for ... accurate application of heat. , ,The ... an assortment of reusable thermal cautery ... the flexibility to perform a wide ...
No Scalpel Vasectomy Ring Clamp, 5 1/2" (14cm), gold finger rings...
Medicine Products: